Abstract
Risk group stratification in early-stage endometrial cancer (EC) is mostly based on clinicopathological characteristics, but more recently also on molecular biomarkers. A deeper molecular knowledge of EC is needed to understand the cellular heterogeneity of the disease and to better predict the prognosis and the benefit of treatments. This study aimed to profile selected immune cell markers by using a multiplexed immunfluorescence approach, and to correlate their expression to patient survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
